Supportive care for patients undergoing immunotherapy

Supportive Care in Cancer

Volumn 25, Issue 10, 2017, Pages 3017-3030

  Rapoport, Bernardo Leon ^a,b   van Eeden, Ronwyn ^a   Sibaud, Vincent ^c   Epstein, Joel B ^d   Klastersky, Jean ^e   Aapro, Matti ^f   Moodley, Devan ^g  

^a Medical Oncology Center of Rosebank   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e JULES BORDET INSTITUTE   (Belgium)

^f CLINIQUE DE GENOLIER   (Switzerland)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Anti CTLA 4; Anti PD 1; Anti PDL 1; Colitis; Endocrinopathy; Immune checkpoint inhibitors; Immune related adverse events; irAE; Nephritis; Pneumonitis; Skin rash; Vitiligo

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLOGIC AGENT; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; ARTICLE; AUTOIMMUNE DISEASE; BLADDER CANCER; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COLITIS; DIARRHEA; ENDOCRINE DISEASE; EYE DISEASE; HEAD AND NECK CANCER; HEART DISEASE; HODGKIN DISEASE; HUMAN; KIDNEY METASTASIS; LICHENOID ERUPTION; LIVER DISEASE; MACULOPAPULAR RASH; METASTATIC MELANOMA; MOUTH DISEASE; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; ONCOLOGIST; PANCREATITIS; PATHOGENESIS; PATIENT CARE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; SKIN TOXICITY; TOXICITY; VITILIGO; WORKSHOP; AUSTRALIA; CHEMICALLY INDUCED; CLASSIFICATION; GASTROINTESTINAL DISEASE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; ORGANIZATION; PALLIATIVE THERAPY; PROCEDURES; SKIN DISEASE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUSTRALIA; AUTOIMMUNE DISEASES; CONGRESSES AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOTHERAPY; MOUTH DISEASES; NEOPLASMS; PALLIATIVE CARE; SKIN DISEASES;

EID: 85023764948     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-017-3802-9     Document Type: Article

References (70)

1. Ryungsa K, Manabu E, Kazuak T (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1–14
2. Chen T, Razak A, Bedard P et al (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26:1824–1829
3. CTCAE v4.0 (2010) https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Last accesed the 03 Jan 2017
4. Bertrand A, Kostine M, Barnetche T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13(211):1–14
5. Tarhini A (2013) Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management, Scientifica (Cairo). No 857519
6. Redman JM, Gibney GT, Atkins MB (2016) Advances in immunotherapy for melanoma. BMC Med 6:14–20
7. Tsiatas M, Grivas P (2016) Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med 14:270
8. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264
9. Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35:2092–2099
10. Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD-1 and anti PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375–2391
11. Belum VR, Benhuri B, Postow MA et al (2016) Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12–25
12. Larkin J, Lao CD, Urba WJ et al (2015) Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 1:433–440
13. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
14. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34
15. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532
16. McDermott DF, Sosman JA, Sznol M et al (2016) Atelizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34(8):833–842
17. Sanlorenzo M, Vujic I, Daud A et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206–1212
18. Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45–51
19. Lo JA, Fisher DE, Flaherty KT (2015) Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol 9:1340–1341
20. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133
21. Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017
22. Minkis K, Garden BC, Wu S et al (2013) The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 69:e121–e128
23. Sibaud V, Meyer N, Lamant L et al (2016) Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 28:254–263
24. Scheberg KB, Novoa RA, Wakelee HA et al (2016) Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 43:339–346
25. Shi VJ, Rodic N, Gettinger S et al (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 152:1128–1136
26. Bonigen J, Raynaud-Donzel C, Hureaux J et al (2016) Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol. doi:10.1111/jdv.14011
27. Johnson DB, Sullivan RJ, Ott PA et al (2016) Ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. JAMA Oncol 2:234–240
28. Jackson LK, Johnson DB, Sosman JA et al (2015) Oral health in oncology: impact of immunotherapy. Support Care 23:1–3
29. Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319
30. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small cell cancer. N Engl J Med 373:123–135
31. Epstein JB, Smutzer G, Doty RL (2016) Understanding the impact of taste changes in oncology care. Support Care Cancer 24:1917–1931
32. Elad S, Jensen SB, Raber-Durlacher JE et al (2015) Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers. Support Care Cancer 23:1615–1622
33. Saunders DP, Epstein JB, Elad SA et al (2013) For the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer 21:3191–3207
34. Elad S, Raber-Durlacher JE, Brennan MT et al (2015) Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer 23:223–236
35. Leenstra JL, Miller RC, Qin R et al (2014) Doxepin rinse versus placebo in the treatment of acute mucositis pain. J Clin Oncol 32:1571–1577
36. Epstein JB, Beier JS (2015) Management of hyposalivation and xerostomia: criteria for treatment strategies. Compend Contin Educ Dent 36(8):600–603
37. Deng J, Jackson L, Epstein JB et al (2015) Dental demineralization and caries in patients with head and neck cancer. Oral Oncol 51:824–831
38. Thorne T, Olson K, Wismer W (2015) A state-of-the-art review of the management and treatment of taste and smell alterations in adult cancer patietns. Support Care Cancer 23:2843–2851
39. Naidoo J, Schindler K, Querfeld C et al (2016) Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4:383–389
40. Weber J, Kahler K, Hauschild A (2015) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:12691–12697
41. Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2(10):1346–1353
42. Weber J, Dummer R, de Pril V et al (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:1675–1682
43. Liu J, Blake S, Smyth R et al (2014) Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunol 3:e22
44. Villadolid J, Amin A (2015) Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4:560–575
45. Bronstein Y, Ng C, Hwu P et al (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992–W1000
46. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
47. Yervoy (ipilimumab) (2103) Princeton, NJ: Bristol-Myers Squibb (package insert)
48. Teply B, Lipson E (2014) Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) 28:30–38
49. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526
50. Zhang X, Ran Y, Wang K et al (2016) Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Des Devel Ther 10:3153–3161
51. Cheng R, Cooper A, Kench J et al (2015) Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30:657–666
52. Tokudome T (2016) Anti-CTLA-4 antibodies immunotherapy of cancer. Edited by Yoshiyuki Yamaguchi. Chapter 18, pp263–282, Springer
53. Kourie HR, Klastersky J (2016) Immune checkpoint inhibitors: side effect and management. Immunotherapy 8:799–807
54. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 anti-body in cancer. N Engl J Med 366:2443–2454
55. Robinson MR, Chan CC, Yang JC et al (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27:478–479
56. Postow M, Wolchok J (2016) Toxicities associated with checkpoint inhibitor immunotherapy. Uptodate http://www.uptodate.com/contents/toxicities-associated-with-checkpoint-inhibitor-immunotherapy. (Last accessed 30 Nov 2016)
57. Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164:303–307
58. Hager T, Seitz B (2014) Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 7:69–77
59. Modjtahedi BS, Maibach H, Park S (2013) Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol 32:341–343
60. Spain L, Walls G, Julve M, et al (2016) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature, Ann Oncol. Published online October 25, 2016. 10.1093/annonc/mdw558
61. Liao B, Shroff S, Kamiya-Matsuoka C et al (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology 16:589–593
62. Simeone E, Grimaldi AM, Esposito A et al (2014) Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 8(240):1–5
63. Akhtari M, Waller EK, Jaye DL et al (2009) Neutropnia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 32:322–324
64. Nair R, Gheith S, Nair S et al (2016) Immunotherapy-associated hemolytic anemia with pure red-cell aplasia. N Engl J Med 374:1096–1097
65. Cortazar FB, Marrone KA, Troxell ML et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638–647
66. Murakami N, Borges TJ, Yamashita M et al (2016) Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J 9:411–417
67. Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297–1306
68. Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755
69. Kushnir I, Wolf I (2017) Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology 136:49–51
70. Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50